Janet Lynch: Drug Pricing Delusion

Janet Lynch: Drug pricing delusion

Editor: You know a policy isn’t sound or realistic when Senator Bernie Sanders comes out and whole-heartedly endorses it. But such is the case when the Administration recently came out and proposed a “Most Favored Nation” policy in drug pricing.…

Ensuring most-favored nation drug pricing doesn’t sicken us

If the U.S. rationalizes how it pays for medicines, consumers, employers, and government payers would see fair prices.

Q&A: What the Most-Favored-Nation Drug Pricing Executive Order Means for Community Pharmacy

Ronna Hauser, PharmD, Senior Vice President of Policy & Pharmacy Affairs at NCPA, provides insights into President Trump’s most recent executive order regarding manufacturer drug prices.

President Trump is Right: Other Nations Need to Pay More for Medicines

President Trump’s push for "Most Favored Nation" pricing is misguided—but he's right to demand other wealthy nations finally pay their fair share for U.S.-developed medicines.

America’s Drug Price Revolution: A Boon for Patients or a Blow to Innovation? - European Biotechnology Magazine

On May 12, 2025, President Donald Trump signed an executive order aiming to drastically reduce U.S. prescription drug prices by aligning them with the lowest prices paid in other developed nations—a policy known as the “Most Favored Nation” (MFN) approach. While the initiative seeks to alleviate the financial burden on American patients, it has sparked intense debate over its potential ramifications on global pharmaceutical trade, investment pat…